Do Increasing Preoperative Timing of Single Dexmedetomidine Dose Have an Effect on Stress Response of Laryngoscopy and Intubation?
NCT ID: NCT07165483
Last Updated: 2025-09-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
45 participants
INTERVENTIONAL
2025-09-11
2026-03-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Dexmedetomidine Infusion Dose Versus Rapid Bolus Dose Before Tracheal Intubation.
NCT06327399
Intratracheal Dexmedetomidine Versus Lidocaine in Eye Surgery
NCT05291221
Effect of Intratracheal Dexmedetomidine Administration on Recovery From General Anesthesia in Pediatrics Undergoing Lower Abdominal Surgery:
NCT04385602
Dexmedetomidine as an Adjuvant in External Oblique Intercostal Plane Block for Post Thoracotomy Pain
NCT06684535
Dexmedetomidine an Effective Drug in Reducing Anesthetic Requirements in External Dacrocystorhinostomy (DCR) Patients
NCT06808295
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Dexmedetomidine, a potent α2-adrenoreceptor agonist, produces not only a sedative-hypnotic effect, but in situations involving cardiac risk, it also produces analgesic effects and an autonomic blocking effect, by acting on a single type of receptor.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group D20
Patients will receive 0.5µg/kg dexmedetomidine (over 10 min) 20 min before induction of anesthesia then saline (over 10 min) 10 min before induction of anesthesia.
Dexmedetomidine
Patients will receive 0.5µg/kg dexmedetomidine (over 10 min) 20 min before induction of anesthesia then saline (over 10 min) 10 min before induction of anesthesia.
Group D10
Patients will receive saline (over 10 min) 20 min before induction of anesthesia then 0.5µg/kg dexmedetomidine (over 10 min) 10 min before induction of anesthesia.
Dexmedetomidine
Patients will receive saline (over 10 min) 20 min before induction of anesthesia then 0.5µg/kg dexmedetomidine (over 10 min) 10 min before induction of anesthesia.
Group C
Patients will receive saline before induction of anesthesia as a control group.
Saline
Patients will receive saline before induction of anesthesia as a control group.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Dexmedetomidine
Patients will receive 0.5µg/kg dexmedetomidine (over 10 min) 20 min before induction of anesthesia then saline (over 10 min) 10 min before induction of anesthesia.
Dexmedetomidine
Patients will receive saline (over 10 min) 20 min before induction of anesthesia then 0.5µg/kg dexmedetomidine (over 10 min) 10 min before induction of anesthesia.
Saline
Patients will receive saline before induction of anesthesia as a control group.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Both sexes.
* American Society of Anesthesiology (ASA) physical status I-II.
Exclusion Criteria
* Respiratory disorders.
* Diabetes.
* Hypertension.
* Obesity.
* Allergic reaction to study drugs.
* Patients on antihypertensive medication (α-methyldopa, clonidine, or other α2-adrenergic agonists)
* Medications that affect heart rate (HR) or blood pressure (BP).
* Pregnant.
* Currently breast-feeding women.
* History of sleep apnea.
* Those for emergency procedures.
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Tanta University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Mohammed Said ElSharkawy
Lecturer of Anesthesiology, Surgical Intensive Care and Pain Medicine, Faculty of Medicine, Tanta University, Tanta, Egypt.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Tanta University
Tanta, El-Gharbia, Egypt
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
36264PR1334/8/25
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.